Most people think generic drugs are cheap because they’re generic. But here’s the truth: bulk buying and tendering are what make them affordable - not just the lack of a brand name. Without these strategies, insurers (and ultimately, policyholders) would be paying far more for the same pills. This isn’t about cutting corners. It’s about smart, data-driven purchasing that cuts out waste in the system.
Back in the 1980s, after the Hatch-Waxman Act passed, the U.S. opened the door for generic drug manufacturers to enter the market. But it wasn’t until insurers and pharmacy benefit managers (PBMs) started using bulk purchasing and competitive bidding that prices really dropped. Today, generics make up over 90% of all prescriptions filled in the U.S., yet they account for less than 18% of total drug spending. That’s because of how they’re bought - not just because they’re cheaper to make.
How Tendering Works: The Bidding Game Behind Your Prescription
Imagine you’re buying 10,000 bottles of a generic blood pressure pill. You don’t just call one supplier and say, "Give me the best price." You send out a request to five or six manufacturers. You tell them: "I’ll buy 2 million units over two years if you give me the lowest price per unit." That’s tendering. It turns drug procurement into a marketplace.
Manufacturers compete not just on cost, but on reliability, supply chain stability, and packaging. The winner gets a long-term contract. The others? They walk away. This pressure keeps prices low. In fact, when a new generic hits the market, prices often drop 80-90% within the first year. A single first-generic approval for a drug like bortezomib saved over $1 billion in its first 12 months. That’s not luck. That’s strategy.
But here’s the catch: not all insurers do this well. Some still rely on outdated formularies - lists of approved drugs - that favor higher-priced generics because of hidden deals between PBMs and manufacturers. These deals are called "spread pricing." A PBM might tell your insurer they paid $1.50 for a pill, but actually paid $0.80. The difference? That’s profit. And it’s buried in your plan’s costs.
The Hidden Cost of Opaque Systems
According to a 2022 study in JAMA Network Open, many insurers don’t even know which generic drugs are driving up their costs. Why? Because MAC lists - Maximum Allowable Cost lists that cap how much insurers will pay for a drug - are often kept secret. You’re told your copay is $10 for a generic. But the real cost to the plan? Maybe $2.50. The rest? Vanishes into the PBM’s margin.
This isn’t just a theory. Real people feel it. One Reddit user paid $87 out-of-pocket for a generic prescription through insurance. When they paid cash at a transparent pharmacy like Cost Plus Drug Company, it cost $4.99. Another user on GoodRx said they save $32 a month by ignoring their insurance entirely. That’s not rare. In 2020, 97% of cash payments for prescriptions were for generics - even though only 4% of all prescriptions were paid in cash. People are figuring it out.
Medicare Part D plans, which cover 40 million seniors, are especially affected. A 2022 report from the Schaeffer Center found that despite generic drugs being cheaper, 78% of these plans still put them on higher cost tiers than brand-name drugs. That means seniors pay more for generics than for branded drugs - even though the generic is often a tenth of the price.
Where Real Savings Happen
The most effective models cut out the middleman. Take Costco. Or Mark Cuban’s Cost Plus Drug Company. They don’t negotiate with PBMs. They buy directly from manufacturers, mark up by a fixed 15%, and pass the rest to customers. Their prices are 75-91% lower than retail pharmacies. A 2023 NIH study found that for expensive generics, the median savings using these models was $231 per prescription. For common ones? $19. Doesn’t sound like much? Multiply that by 10,000 prescriptions. That’s millions saved.
Government programs show it’s possible too. The Veterans Health Administration gets generic drugs at prices 24% lower than Medicare Part D. Why? Because they negotiate directly, without PBM layers. They don’t care about rebate deals. They care about getting the drug to veterans at the lowest possible cost.
What Insurers Are Doing Right
Some insurers are waking up. Blueberry Pharmacy, for example, offers fixed monthly pricing - $15 for blood pressure meds, no surprises. Users on Trustpilot give it a 4.7/5 rating. Why? Because they know what they’re paying. No hidden fees. No formulary games.
Other plans are starting to require transparency. California’s Senate Bill 17, passed in 2017, forces PBMs to disclose any price difference between what they pay pharmacies and what they charge insurers if it exceeds 5%. That’s a start. It forces accountability. When insurers can see the spread, they demand change.
And it’s working. Navitus Health Solutions, a PBM that works with employers, reported 22% lower generic costs in 2023 compared to traditional PBM arrangements. How? They stopped using spread pricing. They paid manufacturers directly. They used tendering to lock in volume discounts. They didn’t hide the math.
The Bigger Problem: Too Few Manufacturers
But here’s the dark side. For many generic drugs, only three companies make them. And if one of them shuts down production - say, because the price is too low - the whole market cracks. In 2020, albuterol inhalers vanished from 87% of U.S. hospitals because manufacturers couldn’t profit at the prices being paid. That’s not a supply chain issue. That’s a procurement failure. When you squeeze prices too hard without ensuring competition, you create shortages.
That’s why smart insurers don’t just chase the lowest bid. They look at how many manufacturers are in the market. They monitor supply chains. They avoid putting all their eggs in one basket. They use tendering to build resilience, not just savings.
What You Can Do - Even If You’re Not an Insurer
You don’t have to be a Fortune 500 company to benefit from these strategies. If you’re paying for prescriptions:
- Check GoodRx or Cost Plus Drug Company before using your insurance. Often, cash price beats insurance copay.
- Ask your pharmacist: "Is there a lower-cost generic alternative?" Many aren’t even aware of cheaper options.
- If you’re on Medicare, ask why your generic is on Tier 3. Push for a tier change.
- For employers: Demand transparency from your PBM. Ask for the spread pricing data. If they refuse, switch.
The system isn’t broken. It’s just rigged. But it’s rigged because no one asked questions. People assumed generics were cheap. They didn’t realize how much was being hidden.
The truth? Generics are the biggest cost-saver in healthcare. But only if they’re bought the right way. Bulk buying and tendering aren’t fancy terms. They’re basic business. And when insurers use them well, everyone wins - especially the people who need the pills.
How do bulk buying and tendering actually lower drug prices?
Bulk buying works by combining the purchasing power of many patients into one large order. Insurers or PBMs then invite multiple generic manufacturers to bid on supplying that volume. The lowest bidder wins a long-term contract. This competition drives prices down - often by 80-90% from initial launch prices. The more manufacturers competing, the bigger the savings.
Why do some insurance plans charge more for generics than brand-name drugs?
It’s usually because of how formularies are structured and how PBMs make money. Some PBMs earn more when a higher-priced generic is prescribed, thanks to hidden rebates and spread pricing. Even if the generic costs less to produce, the insurer may still be charged more, and that cost gets passed to the patient through higher copays. This is why some Medicare plans put generics on higher tiers - not because they’re expensive, but because of financial incentives built into the system.
What’s the difference between a PBM and direct-to-consumer pharmacies like Cost Plus Drug Company?
A PBM acts as a middleman between insurers, pharmacies, and manufacturers. They negotiate prices, manage formularies, and often profit from the difference between what they pay pharmacies and what they charge insurers (spread pricing). Direct-to-consumer pharmacies like Cost Plus Drug Company cut out the PBM entirely. They buy directly from manufacturers, add a fixed markup (often 15%), and sell at transparent prices. That’s why their prices are often 75-90% lower than retail.
Can tendering cause drug shortages?
Yes. When insurers or PBMs demand prices so low that manufacturers can’t cover production costs, some stop making the drug. This happened with albuterol inhalers in 2020 - prices dropped below $1 per unit, and 87% of hospitals ran out. Smart tendering doesn’t just chase the lowest bid. It ensures enough manufacturers are involved so that if one drops out, others can step in.
How can I tell if my insurance is overpaying for my generic drugs?
Compare your insurance copay to the cash price at pharmacies like Costco, Walmart, or GoodRx. If the cash price is lower - especially by more than $10 - your plan is likely paying more than it needs to. Also, check if your generic is on a higher tier than brand-name drugs. If so, ask your insurer why. You may be able to get it moved to a lower tier.
